ArticleTransplantation direct2025
Extracorporeal Photopheresis: Secreted Factors That Promote Immunomodulation.
Article in Transplantation direct, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Exploring the Role of Extracorporeal Photopheresis in Kidney Transplant Management.Transplantation direct · 2025Article
- ECP-induced Apoptosis: How Noninflammatory Cell Death Counterbalances Ischemia/Reperfusion Injury.Transplantation direct · 2025Article
- Potential Biomarkers of Therapeutic Response to ECP in Solid Organ Transplantation.Transplantation direct · 2025Article
- exTra Mini-review Series on ECP in Transplantation.Transplantation direct · 2025Article
- Extracorporeal Photopheresis in Lung Transplantation: Present Applications and Emerging Research.Transplantation direct · 2025Article
- Potential Impact of Extracorporeal Photopheresis on Trained Immunity and Organ Transplant Acceptance.Transplantation direct · 2025Article
- Extracorporeal Photopheresis: Does It Have a Potential Place Among Cell-based Therapies?Transplantation direct · 2025Article
- Extracorporeal Photopheresis Stimulates Tissue Repair after Transplantation.Transplantation direct · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extracorporeal photopheresis (ECP) is a therapy indicated for various T cell-mediated conditions, including cutaneous T-cell lymphoma (CTCL), graft-versus-host disease (GVHD), and solid organ transplant rejection. ECP comprises the treatment of patients' leukocytes with 8-methoxypsoralen and ultraviolet-A light followed by autologous reinfusion. ECP exerts therapeutic immune-stimulatory effects in CTCL and immune regulatory effects in GVHD and solid organ transplant rejection. Besides cellular mediators, secreted molecules can contribute to ECP's therapeutic effect. Methods: We conducted a comprehensive review of the literature on ECP-induced secreted factors and their immunomodulatory roles. Results: 8-Methoxypsoralen/ultraviolet-A treatment drives leukocyte apoptosis, resulting in the release of damage-associated molecular patterns that promote apoptotic cell phagocytosis by dendritic cells (DCs) and promote or impair DC maturation. In CTCL, the increased production of proinflammatory cytokines in photopheresates, including interferon-γ, interleukin (IL)-2, tumor necrosis factor-α, IL-1β, and IL-8, is linked to antitumor responses. Conversely, ECP upregulates anti-inflammatory cytokine production in photopheresates from GVHD patients' cells. Upon reinfusion of photopheresates containing anti-inflammatory factors, untreated immature DCs are converted to tolerogenic DCs with increased IL-10 and transforming growth factor-β secretion and regulatory T cell-inducing functions. In allograft models, ECP increases IL-4, IL-10, and IL-13, which reduce allograft rejection. Moreover, ECP influences the level of immunomodulatory metabolites and the composition of exosomes. However, further research, for example, using multi-omics approaches, are needed to provide a more comprehensive picture of the ECP-induced secretome and to identify relevant factors that could contribute to ECP's therapeutic effects. Conclusions: ECP induces the release of different pro/anti-inflammatory factors in different preexisting conditions that determine different DC maturation status and immunomodulatory effects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.